BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17372254)

  • 1. Epistatic relationship between the cancer susceptibility genes CHEK2 and p27.
    Cybulski C; Gliniewicz B; Sikorski A; Kładny J; Huzarski T; Gronwald J; Byrski T; Debniak T; Gorski B; Jakubowska A; Wokolorczyk D; Narod SA; Lubiñski J
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):572-6. PubMed ID: 17372254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
    Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
    Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of breast cancer associated with CHEK2*1100delC.
    Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
    J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
    Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
    Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
    Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
    Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.
    Serrano-Fernández P; Debniak T; Górski B; Bogdanova N; Dörk T; Cybulski C; Huzarski T; Byrski T; Gronwald J; Wokołorczyk D; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2009 Sep; 117(1):161-5. PubMed ID: 19030985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
    Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk.
    Einarsdóttir K; Humphreys K; Bonnard C; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
    Hum Mol Genet; 2007 Jan; 16(2):154-64. PubMed ID: 17164260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
    Wasielewski M; Hanifi-Moghaddam P; Hollestelle A; Merajver SD; van den Ouweland A; Klijn JG; Ethier SP; Schutte M
    Breast Cancer Res Treat; 2009 Jan; 113(2):285-91. PubMed ID: 18297428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CHEK2 mutations in prostate cancer.
    Wu X; Dong X; Liu W; Chen J
    Hum Mutat; 2006 Aug; 27(8):742-7. PubMed ID: 16835864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
    van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
    J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J
    J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer and the CHEK2 1100delC mutation.
    de Jong MM; Nolte IM; Te Meerman GJ; van der Graaf WT; Mulder MJ; van der Steege G; Bruinenberg M; Schaapveld M; Niessen RC; Berends MJ; Sijmons RH; Hofstra RM; de Vries EG; Kleibeuker JH
    Genes Chromosomes Cancer; 2005 Aug; 43(4):377-82. PubMed ID: 15852425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHEK2 I157T and colorectal cancer in Bulgaria.
    Konstantinova D; Kadiyska T; Sokolova V; Kaneva R; Mirchev M; Savov A; Aleksandrova A; Nedin D; Kostadinov E; Damyanov D; Kremensky I; Mitev V
    J BUON; 2010; 15(2):314-7. PubMed ID: 20658728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATM missense variant P1054R predisposes to prostate cancer.
    Meyer A; Wilhelm B; Dörk T; Bremer M; Baumann R; Karstens JH; Machtens S
    Radiother Oncol; 2007 Jun; 83(3):283-8. PubMed ID: 17502119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer.
    Zhang S; Lu J; Zhao X; Wu W; Wang H; Lu J; Wu Q; Chen X; Fan W; Chen H; Wang F; Hu Z; Jin L; Wei Q; Shen H; Huang W; Lu D
    Carcinogenesis; 2010 Jul; 31(7):1251-8. PubMed ID: 20462940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.